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ABSTRACT 
 
Azinomycin B is an antitumor agent isolated from the soil bacteria Streptomyces 
sahachiroi. The complex molecular structure of azinomycin B contains a bioactive 
aziridine ring and an epoxide moiety, which are the major structural components 
responsible for the natural product’s antitumor bioactivity. In this study, we attempt to 
characterize the early steps of azinomycin B’s aziridine-containing azabicycle fragment 
biosynthesis and subsequently further elaborate on our existing knowledge on the overall 
biosynthesis of azinomycin B.  
Previous attempt to characterize AziC2 suggested that the first step of 
azinomycin B’s azabicycle fragment formation involves the transfer of L-glutamate, the 
amino-acid precursor, to downstream biosynthetic enzymes through the catalytic activity 
of a putative N-acetyltransferase (AziC2), which utilizes acetyl-CoA as a feasible acetyl 
group donor. Interestingly, by closely examining the azinomycin B’s biosynthetic gene 
cluster and related homologs, we identified a previously uncharacterized protein AziW 
that may acts as an alternative acetyl group donor for AziC2. In addition, BLAST studies 
had proposed that AziC2 might potentially confer unrevealed phosphatase activity and 
function in conjunction with the novel AziW during the biosynthesis of azinomycin B’s 
azabicyclic moiety. To characterize the relationship between AziC2 and AziW, we 
performed radiolabeled feeding studies. The result from these labeling experiments 
indicated that the C-terminal of AziW is independently phosphorylated via self-
activation in the presence of ATP. Most importantly, this phosphorylation event occurs 
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prior to the transfer of L-glutamate by AziC2.  These findings suggest that AziC2 only 
acts an acetyltransferase but not as a phosphatase towards AziW during the biosynthesis 
of azinomycin B’s azabicycle fragment. In addition, our labeling experiments and 
feeding studies also confirmed the functions of AziC3 and AziC4 as kinase and 
reductase respectively. This dissertation also includes our ongoing progress with AziH1, 
AziH2 and AziH3 which are responsible for the formation of the aziridine ring. The 
potential interaction between AziW and its enzymatic partners may offer advanced 
insights on the regulation mechanism involved in the biosynthesis of azinomycin B and 
help decipher the complex enzymology that highlights the biosynthesis of related natural 
products. 
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CHAPTER I 
 
INTRODUCTION: BIOSYNTHESIS OF NATURAL PRODUCT 
NATURAL PRODUCT OVER THE YEARS 
 For the past half-century, approximately 50% of small molecules that exhibit 
antitumor activities are derived from natural products (Figure 1).1 Early approach in 
screening large libraries of synthetic compounds for efficacy largely relied on 
combinatorial chemistry technology.2 However, this combinatorial approach failed to 
yield a significant amount of new drugs during the past 30 years, with sorafenib/ 
Nexavar® as the only rare case of success. Consequently, this led researchers to 
primarily focus on using smaller collections of structurally related compounds with 
defined natural product origins. As a result of this new approach, the majority of drugs 
discovered in the past decade are natural product derivations. In addition, natural 
product-derived compounds accounted for 50% of the total small molecule approved 
drugs in 2010 (Figure 2). Most importantly, the ongoing effort to exploit the clinical 
potential of nature’s chemical reservoir continues to perpetuate the necessary 
development of more potent and nontoxic drugs for clinical use. 
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Figure 1 The distribution of anticancer drugs from 1940s to 2010. Total number of drugs =206. N: Natural 
product; NB: Natural product- Botanical; ND: Natural product derivatives; S: Totally synthetic drug, often 
found by random screening/modification of an existing agent; S*: Totally synthetic drug but the 
pharmacophore is/ was from a natural product; V: Vaccine; B: Biological, includes peptide or protein 
isolated from an organism/cell line or biotechnologically produced in a surrogate host. Subcategory (NM: 
Natural product minic) Adapted from Newman et al. [1]. 
 
 
 
 
 
Figure 2 The percentage of drugs in the N/NB/ND categories from 1981-2012. Adapted from Newman et 
al. [1]. 
 
 
 
Most of the novel therapeutic agents developed in the past decade are natural 
products or inspired by the structures of natural products. Figure 3 offers some examples 
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of drugs isolated from natural resources or structurally originated from natural products.3 
Many of these natural product-derived small molecules exhibit diverse and potent 
bioactivities. For example, taxol® (3a) is an antitumor drug isolated from the stem bark 
of Pacific yew tree, Taxus breuifolia.4 This natural product effectively inhibits mitosis 
via microtubule over-stabilization.5 On the other hand, rapamycin/ Sirolimus®(3b), 
produced by Streptomyces hygroscopicus, is routinely used as an antifungal antibiotic.6 
Simvastatin/ Zocor® (3c) is a structurally modified analog of the natural product 
lovastatin, a metabolite from Aspergillus terreus, and it acts as a hypolipidemic agent.7 
Finally, Cytarabine/ Depocyt® (3d), is a synthetic antitumor agent derived from 
metabolites of a marine organism Cryptotheca crypta.8 
 
 
 
 
 
Figure 3 Examples of drugs inspired by natural products. a. Taxol®; b. Rapamycin/ Sirolimus®; c. 
Simvastatin/ Zocor®; d. Cytarabine/ Depocyt® 
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SYNTHETIC BIOLOGY OF NATURAL PRODUCTS 
 Natural products are produced by organisms through a devoted biosynthetic 
pathway and tailored by nature in response to different biological targets. Their chemical 
structures are usually very complex and require cellular modification that may not be 
replicable using synthetic methodology. Not only is organic synthesis of complex natural 
product as therapeutic agent very laborious and time-consuming, it may also generate 
harmful reaction side products and ultimately result in a very low yield. Therefore 
synthetic approach is not ideal and commercially unfeasible. In contrary, synthetic 
biology approach, where the site specific enzymatic reaction can eliminate complicated 
protection and deprotection steps in total synthesis; simple synthetic route can be used to 
replace redundant enzymes.  
THE HISTORY OF AZINOMYCINS 
Azinomycin B (Figure 4), originally called carzinophilin A, was first isolated 
from Streptomyces sahachiroi by Hata et al. in Tokyo in 1954. Initially, this bacterial 
strain was found to inhibit a malignant tumor, Yoshida sarcoma, and prolong the lifespan 
in treated rats with the cancer.9 Shortly after the discovery of the natural product, the 
clinical studies of carzinophilin A were reported.10 Soon afterward, the advancement of 
isolation and spectroscopic technique led to the complete structural characterization of 
carzinophilin A (Figure 5). The molecular formula of carzinophilin A was first reported 
as C60H60O21N6, but later corrected to C50H58O18N5 by Tanaka et al.in 1959. They also 
reported the partial structure of carzinophilin A contains 3-methoxy-5-
methylnaphthalene-2-carboxylic acid (5a) by fragmenting the molecule using alkaline 
 
 
5 
 
hydrolysis. 11-13 Onda et al. repeated the alkaline hydrolysis of carzinophilin A in 1971 
and reassigned the substituents on the naphthoate moiety to give 3-methoxy-5-
methylnaphthalene-1-carboxylic acid (5b).14 In 1982, a more complete structure of 
carzinophilin A, as a dimerized molecule, is reported by Lown in congruent with his 
previous studies based on the natural product’s DNA interstrand crosslinking properties 
(5c).15 Further studies by Onda et al.in 1983 and 1984 suggested two more different 
structures (5d, 5e).11, 16 In 1986, over 30 years after carzinophilin A was first isolated, 
the actual structure of carzinophilin A was finally determined by Yokoi et al. The result 
of this discovery gave rise to the existence of azinomycin B (5f). In addition to 
azinomycin B, other metabolites including azinomycin A and naphthoate derivatives, 
were also identified.17 
 
 
 
 
 
Figure 4 Structure of the azinomycin B (a) and azinomycin A (b) isolated from Streptomyces sahachiroi. 
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Figure 5 Proposed structures for Carzinophilin A/ Azinomycin B. 
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STREPTOMYCES, NATURAL PRODUCTS AND BIOSYNTHESIS 
 Streptomycetes are gram-positive soil dwelling bacteria that constitute the largest 
genus of Actinobacteria.18 These filamentous fungus-like bacteria generate aerial 
branches to form spores with muddy odor. They consume plant materials and fungus for 
nutrients, and promote self-defense by secreting antibiotics during reproductive phase 
against invading pathogens/bacteria.19 Streptomycetes produce numerous natural 
antibiotics and a wide range of bioactive secondary metabolites that can be used as 
anticancer drugs, antifungals and immunosupressants 6, 20, 21. Majority of the antibiotics 
found in medical use are naturally-derived from Streptomycetes, such as neomycin from 
S. fradiae; streptomycin from S. griseus; and vancomycin from S. orientalis. The 
complete sequencing of the first Streptomyces genome in 2002 had encouraged the 
industry to employ Steptomycetes microorganism for secondary metabolites production 
to screen for active compounds.22, 23 Since then, the biosynthetic pathways and the mode 
of action of these compounds had been heavily studied and researched. However, at 
times, potent therapeutic agents fell short in clinical application due to poor solubility 
and high toxicity. Consequently, studying the biosynthetic pathway of natural product 
will subsequently benefit future drug design in favor of improving the 
pharmacokinetics/pharmacodynamics of these compounds.24  
THE ANTITUMOR AGENT AZINOMYCIN B 
Azinomycin A and azinomycin B (Figure 4), were not identified until they are re-
isolated from Streptomyces griseofuscus in 1986.25,26 These compounds are slightly 
different in structure but they sustain unique bioactivity. Current focus on azinomyzin B 
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is due to its significant cytotoxic effect. Cytotoxicity studies showed that azinomycin B 
is highly cytotoxic against the leukemia cell line L5178Y (IC50 = 0.11µg/mL).
27 In other 
mouse model studies, treatment of azinoymcin B also led to increased life span (ILS) of 
193% (32µg/kg) in P388 leukemia mouse models. In comparison to the 
chemotherapeutic mitomycin C (increased life span (ILS) of 204% (1mg/kg)), 
azinoymcin B proves to be more potent at a lower dosage.28  
As a potent antitumor agent, azinomycin B binds to the major groove of DNA 
and introduces DNA interstrand cross-links.29,30  As illustrated in Figure 6, this mode of 
interaction with double stranded DNA is responsible for its anti-tumor activity. The 
nitrogen N7 of a suitably disposed purine bases of DNA attacks the electrophilic carbon 
C10 of the aziridine ring system or the carbon C21 of the epoxide moiety in azinomycin 
B, which leads to DNA alkylation. Ultimately, this deadly interaction triggers damages 
in the double-strand that are not repairable.31  
 
 
Figure 6 Mode of action: DNA alkylation of azinomycin B. 
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AZINOMYCIN B BIOSYNTHETIC PATHWAY 
 Aziridine-containing natural products are rare and fascinating secondary 
metabolites that. Specifically, azinomycin B is the only aziridine-containing natural 
products with its gene cluster completely published.32 The aziridine functional group in 
azinomycin B is believed to contribute much to the natural product’s cytotoxicity in 
living cells, making it an interesting candidate to study from the biosynthetic and 
functional perspective. 
 The first biosynthetic study of azinomycin B was carried out by Corre and 
Lowden via feeding labeled 13C-acetate precursors, including [1- or 2- or 1, 2-13C]-
acetate, into the fermentation cultures of Streptomyces sahachiroi. Azinomycin B, 
incorporated with the 13C label, was isolated and analyzed using 13C-NMR spectroscopy. 
The result confirmed the polyketide synthase-oriented naphthoate fragment is assembled 
from one acetyl-CoA and five malonyl-CoA units.33 Further studies using synthetic 
naphthoic acids with deuterated methyl group showed that the formation of the 
naphthoate moiety is completed before integrating into the molecule.34 The incorporation 
of the doubly-labeled [1, 2-13C]-acetate into the enol fragment (2-13C in C1 and C4; 1-
13C in C1 to C4) and the [1-13C] acetyl group into C13 of the aziridine fragment, 
suggested threonine and α-ketoglutarate are possibly the building blocks of these moiety 
respectively.33 When [U-13C] threonine was supplied to the fermentation culture, the 
enol fragment was specifically labeled, which indicates threonine is the precursor of the 
keto-enol portion of azinomycin B. The epoxide moiety of azinomycin B was evaluated 
using [1-13C]-valine derivatives and analyzed based on the relative 13C incorporation. L-
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valine was finally validated as the precursor of the epoxide moiety where it undergoes a 
series of hydroxylation, transamination, and dehydration to form 3-methyl-2-
oxobutenoate before ligating onto the final structure of azinomycin B (Figure 7).35,36 
 
 
 
 
 
Figure 7 Evaluation of the biosynthetic origins of azinomycin B.  
 
 
In 2008, Zhao et al. successfully identified the biosynthetic gene cluster of 
azinomycin B using PCR screening. A library of S. sahachiroi genome was created and 
PCR probes were used to screen thousands of clones. By locating overlapped cosmids 
and using chromosome walking techniques, they revealed an 80kb DNA region 
representing the azinomycin B gene cluster (Figure 8). 32   
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Figure 8 The gene cluster of azinomycin B. Adapted and modified from Zhao et al. [32]. 
 
 
 
The genes encoding the building blocks of azinomycin B were proposed based 
on bioinformatics analysis. Sequence similarity and domain organization suggest aziB is 
the PKS gene responsible for the formation of 5-methyl-naphthoic acid. Modification of 
5-methyl-naphthoic acid by aziB1 and aziB2 gives the final naphthoate fragment 3-
methoxy-5-methyl-naphthoic acid. The formation of the azabicycle moiety may involve 
up to ten genes, aziC2 to azi11, but the detailed mechanism in how the five-membered 
ring and the aziridine ring are formed still remains unknown. Different building blocks 
are joined together and tailored by the peptide carrier domain (PCP) encoded by the 
nonribosomal peptide synthetases (NRPS) genes, aziA1 to aziA5. The biosynthetic 
pathway proposed by Zhao et al. is outlined in Figure 9. 32  
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Figure 9 Suggested biosynthetic pathway of azinomycin B fragments. AL: aldolase; PCP: peptide carrier 
protein; C: condensation; KR: ketoreductase; A: adenylation. 
 
 
 
Enzymatic studies of the azinomycin B biosynthesis are ongoing after the 
publication of its gene cluster. According to an in vivo study by Ding et al., heterologous 
expression of the PKS AziB confirmed the production of 5-methyl naphthoic acid. The 
use of the P450 hydroxylase AziB1 along with the O-methyltransferase AziB2 resulted 
in the formation of 3-hydroxy-5-methyl-naphthoic acid, as shown in both in vivo and in 
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vitro HPLC analysis. The NRPS AziA1 was found to activate the 3-methoxy-5-methyl-
naphthoic acid by using ATP-[32P]-PPi exchange study. 37 aziR, located outside the 
azinomycin B gene cluster, was characterized as a resistance protein through 
heterologous expression and the examination of in-cell protective effect.38 Gene 
knockout study of aziU1 through aziU3 reduced azinomycin B production in 
fermentation media.39 Up to this date, the effort to paint the entire picture of the 
azinomycin B biosynthesis is still ongoing.  
THE AZABICYCLE BIOSYNTHESIS 
 Natural products consist of various kinds of three-membered ring structures, such 
as aziridine, cyclopropone and epoxide, which usually possess antibiotic and/or 
antitumor activities.40-43 Ring opening of the strained ring system triggers site-specific 
electrophilic attack that results in DNA alkylation. Therefore, many researchers are 
interested in understanding how these strained bioactive structural moiety are chemically 
tolerated and biosynthetically made. In the case of azinomyicin B biosynthesis, the 
assembly of cyclopropane uses isoprenoid pyrophosphates as their building block. 
Intermolecular alkylation by prenyltransferase or intramolecular alkylation by terpene 
synthase release pyrophosphate and generate a carbocationic intermediate which 
undergoes electrophilic addition, rearrangements, and finally quenched to give the final 
cyclized product.44-46 The P450-dependent epoxide formation involves oxygen bond 
cleavage to generate a cationic radical that reacts with the alkene. The change of Fe 
oxidation state stabilizes reactive radical species to achieve the incorporation. The 
catalytic cycle is regenerated by a water molecule. 46-49 Due to the rarity of gene cluster 
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published for aziridine-containing natural products, the aziridine formation is by far the 
least understood compare to the cyclopropane and epoxide moieties. Bicker and Fischer 
reported an observation that involves the sulfate donor, 3'-phosphoadenosine-5'-
phosphosulfate (PAPS), in the pronethalol aziridine biosynthesis. The hydroxyl group is 
sulfated by PAPS via sulfotransferase. Sulfate is a better leaving group than the hydroxyl 
group and facilitates the aziridine ring closure (Figure 10).50    
 
 
 
 
 
Figure 10 The proposed PAPS-dependent aziridine formation.  
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CHAPTER II 
 
AZIW, A PROTEIN INVOLVES IN THE AZABICYCLE BIOSYNTHESIS OF 
AZINOMYCIN B 
INTRODUCTION 
 The gene cluster of azinomycin B (Figure 8) is identified using heterologous 
expression studies in the host organism Scaphirhynchus albus. It discloses an iterative 
type I polyketide synthase (PKS) and five nonribosomal peptide synthetases (NRPS) 
responsible for the assembly of its core structure. Several other genes encoding the 
amino acid-derived building blocks, resistant proteins and tailoring steps are proposed 
but not characterized. As shown in the previous chapter, the azabicycle fragment of 
azinomycin B contains the bioactive aziridine group. My research focused on 
characterizing the proteins involved in the formation of the azabicycle moiety because 
understanding its biosynthetic origin will provide possible strategies to enhance the 
stability and bioactivity of azinomycin B for future drug development.  
13-C labeled feeding studies performed by former Watanabe group members had 
identified a few potential amino acid precursors to the azabicycle system.35-36,51-52 The 
scrambling incorporation of labeled [1-13C], [2-13C] and [1,2-13C] acetates at the C6-C7 
and C12-C13 positions of azinomycin B suggests the contribution of a α-ketoglutarate. 
Possible precursors to α-ketoglutarate include proline, arginine, glutamine and 
glutamate, which would give raise to the azabicycle structure.51 Knocking out aziC2 and 
feeding the disruptant fermentation culture with potential isotopically labeled amino 
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acids had narrowed down the choice of precursors to L-glutamate. This chapter discusses 
the discovery of an unusual protein AziW, which mediates L-glutamate in the azabicycle 
formation.  
RESULTS AND DISCUSSION 
Bioinformatics Analysis and Previous Studies 
aziW is located upstream of aziC4 and it is not annotated in the published 
azinomycin B gene cluster. AziW is homologous (50% sequence identity) to the 
bacterial protein LysW (Figure 11). LysW has been shown to play a role during lysine 
biosynthesis in Thermus thermophilus. It contains a globular domain and a conserved C-
terminal amino acid sequence EDWGE. The γ-carboxyl group of the C-terminal 
glutamate of LysW conjugates and modifies the amino group of α-aminoadipic acid 
(AAA). The LysW-AAA conjugation is activated by the protein LysX, an ATP-
dependent ligase/acetyltransferase, through ATP phosphorylation. In addition, LysW 
also acts as a carrier protein in which its globular domain interacts electrostatically with 
other enzymes and mediates the formation of lysine (Figure 12).53 
 
 
 
 
 
Figure 11 Amino acid sequence alignment of LysW homologs from different species. 
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Figure 12 The proposed functional roles of LysW in lysine biosynthesis of Thermus thermophiles.          
LysW acts as a protein carrier (Left) and ATP-dependent ligase (Right). 
 
 
 
The amino acid sequence alignment of AziC2 (Streptomyces sahachiroi) and 
LysX (Thermus thermophilus) showed significant sequence identity (44%). The 
conserved regions that are important for LysW-LysX interaction in Thermus 
thermophilus are also present in AziC2. According to the protein BLAST, AziC2 has 
some similarities to the ATP-grasp superfamily. Enzyme in this family catalyzes the 
ligation of the carboxylate group and the amine/thiol group of two different molecules 
using ATP. Some examples are D-alanine-D-alanine ligase, glutathione synthetase, and 
ribosomal S6 modification enzyme RimK (Appendix Figure I). Based on this 
information, we proposed a similar pathway in which AziC2 activates the ligation of 
AziW and L-glutamate using ATP (Figure 13). The putative lysine biosynthetic gene 
cluster of all microorganisms that synthesizes lysine through a similar pathway has the 
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lysW located right next to the lysX. In case of aziW, it is very distant from aziC2 in the 
azinomycin B gene cluster (Appendix Figure II).  
 
 
 
 
 
Figure 13 The proposed function of AziW and AziC2. 
 
 
 
Previous isotope-feeding experiments had identified L-glutamate as the precursor 
responsible for the assembly of the azabicycle moiety of azinomycin B. According to the 
in vitro studies performed by Dinesh Simkhada (Former post-doctoral, Watanabe group), 
AziC2 acts as an N-acetyltransferase. It catalyzes the formation of N-acetyl-L-glutamate 
using acetyl-CoA and L-glutamate. HPLC analysis of in vivo gene knockout of aziC2 
completely halted the azinomycin B production. However, feeding the mutant strain 
fermentation media with N-acetyl-L-glutamate did not restore the azinomycin B 
production as expected (unpublished data). This result led us to suspect whether acetyl-
CoA is the original substrate for AziC2. Literature review revealed the presence of a 
small gene aziW in the azinomycin B gene cluster. Being a homolog to the LysW of 
Thermus thermophilus, we investigated the role of AziW.  
A similar gene knockout study of aziW performed by Hillary Agbo (PhD, 
Watanabe group) showed no effect in azinomycin B production. However, disruption of 
aziW reduced the transcription level of the genes downstream of it (unpublished data). 
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To examine whether AziW or acetyl-CoA is the original substrate and to understand the 
role of AziW in the azabicycle biosynthesis, in vitro analysis of AziW with AziC2 were 
carried out.  
Inorganic Phosphate Detection by Malachite Green Assay 
 aziW and aziC2 were amplified from the genomic DNA of S. sahachiroi and 
introduced into the vector pET24b for protein overexpression. The inserts were verified 
by DNA sequencing reaction. aziW-pET24b and aziC2-pET24a were expressed in the E. 
coli BL21(DE3) strain via IPTG induction. The proteins were purified using His-Trap 
columns, confirmed by SDS-PAGE gel, and concentrated prior to in vitro assays. 
 Assuming AziC2 is a phosphatase, inorganic free phosphate would be released 
during the enzymatic reaction. Initial experiment was to monitor the release of free 
phosphate using malachite green assay kit (Cayman Chemicals). The complex formed 
between inorganic phosphate and malachite green molybdate under acidic condition can 
be measured spectrophotometrically at 620 nm. By comparing to the phosphate 
standards, we estimated the concentration of free phosphate being released in the 
reaction. 
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Figure 14 Malachite green assay of AziC2 and AziW. 
 
 
 
This result showed the release of approximately 0.5 nmole free phosphate per 
100 μL of reaction mixture. In addition, it confirmed L-glutamate is the substrate rather 
tahn DL-2-aminoadipic acid as no free phosphate was detected compare to the control 
(Figure 14). 
Radioactive Labeling Assays 
To further understand how the inorganic phosphates were produced, we replaced 
ATP with [γ-32P]-ATP in the reaction. Reactions containing purified protein(s) AziW 
and AziC2, [γ-32P]-ATP and/or L-glutamate were set up. The proteins were loaded into a 
15% SDS-PAGE gel after the reaction. The image of the gel was visualized using 
autoradiography (Figure 15).  
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Figure 15 Result of [γ-32P]-ATP study. 15% SDS-PAGE gel (left) and reaction conditions (right). 
 
 
 
The dark bands shown on the gel image are [32P] labeled AziW according to the 
distance the protein traveled on the SDS-PAGE gel. AziW in Lane#1 is [32P] labeled; 
AziW in Lane#2 is also [32P] labeled but at a lower concentration. In the absence of L-
glutamate, AziW is expected to be labeled by [32P]. The presence of L-glutamate, 
however, may or may not result in [32P] labeled AziW depending on the substrates’ ratio 
and if the reaction had gone to completion. In a control setup (Lane 3) where no AziW is 
added in the reaction mixture, no band is observed on the gel. Surprisingly, in another 
control setup (Lane 4) where no AziC2 was added, AziW is still being [32P] labeled. This 
suggests the possibility of AziW self-activation in the phosphorylating process and that 
AziC2 may only involve in the transfer of L-glutamate to AziW.  
To determine the role of AziC2, a similar experiment was performed using L-
[14C(U)]-glutamate in place of the L-glutamate. Reactions containing purified AziW and 
AziC2, L-[14C(U)]-glutamate, and ATP were used. The image of the SDS-PAGE gel is 
shown below (Figure 16).  
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Figure 16 Result of [14C]-glutamate study. 15% SDS-PAGE gel (left) and reaction conditions (right). 
 
 
 
Due to the low-level radioactivity of [14C], a faint band representing labeled 
AziW (Lane 1) showed up on the gel after prolonged exposure. This result is consistent 
with our prediction in which AziC2 only acts as a transferase. AziW is [14C] labeled in 
the presence of AziC2 but not in the absence of it. No band is observed in the controls 
(Lane 2 and Lane 3). The band in Lane 4 was not observed due to low intensity. This 
result supports the hypothesis that phosphorylation of AziW is self-activated and the 
ligation of L-glutamate afterward is done by AziC2.  
SIGNIFICANCE 
 AziW has been shown to take part in the reaction under the assayed conditions. 
Inorganic phosphates were detected in the malachite green assay which indicates the 
consumption of ATP during the reaction. [γ-32P]-ATP radioactive labeling study clearly 
showed the incorporation of [32P] in AziW. Since the proteins were heat denatured prior 
to loading into the SDS-PAGE gel, a bond is formed between the C-terminal carboxylic 
group of AziW and [32-P]. The result of the L-[14C(U)]-glutamate labeling experiment 
though promising has the necessity to repeat it using signal intensifier. Unlike the LysW 
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and LysX of Thermus thermophilus, AziW appears to be phosphorylated via self-
activation and AziC2 serves only as a transferase in our case.  
The preliminary results for characterizing AziW support our hypothesis so far. 
Future plan is to detect the L-glutamate linked-AziW intermediate using protein mass 
spectrometry. We will also attempt to differentiate the bands for AziW and L-glutamate 
linked-AziW in the reaction mixture using a higher resolution 12% Tricine-SDS-PAGE 
protein gel (resolution <2kDa) and analyze them using protein mass spectrometry. In 
addition, we can validate the reaction site, the C-terminal glutamate, of AziW via in vitro 
analysis with AziC2 using mutant AziW containing different amino acid, such as 
glutamine, alanine, valine or leucine, in place of the C-terminal glutamate. A custom-
made AziW with an additional L-glutamate in its C-terminal may be used to feed into 
the AziC2 disruptant fermentation broth follow by HPLC analysis of azinomycin B 
production. 
EXPERIMENTAL PROCEDURES 
Instrumentation and General Methods 
All primers used for DNA amplifications were ordered through Gene 
Technologies Lab (GTL) at Texas A&M University. DNA sequencing was also 
performed by GTL. All chemicals were purchased from Sigma-Aldrich. Malachite green 
phosphate assay kit was purchased from the Cayman Chemical. Radioactive labeled 
compounds were obtained from Perkin Elmer. Inorganic phosphate concentrations were 
determined in a 96-well plate using BioTek FL800 fluorescence microplate reader. 
Protein concentrations were analyzed via Bradford method (Standard: Bovine serum 
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albumin with linear range of 0.5 mg/mL to 5 mg/mL). Autoradiograph is developed 
using Fuji X-ray film developer. Primers, plasmids and strains used in this study are 
listed in Table 1. The map of the plasmid constructs is presented in Appendix Figure 4. 
 
 
 
Table 1 Primers, plasmids and strains used in the AziC2 and AziW studies. 
 
Primer/ plasmid/ 
strain 
Description Source 
Primers   
lysW_EcoRI _F GAATTCATGCACCACCACCACCACCACACTA
CGGCGCTGAGCGTGC 
This study 
lysW_HindIII_R AAGCTTCTACTCGCCCCAGTCCTCTTCG This study 
   
Plasmids   
pET-24a T7 expression vector, C-terminal His6-Tag, 
Kanamycin resistance 
Novagen 
pET-24b T7 expression vector, C-terminal His6-Tag, 
Kanamycin resistance 
Novagen 
pET24a-aziC2 aziC2 gene (861 bp) was inserted at BamHI and 
HindIII sites 
Dinesh 
Simkahda 
pET24b-aziW aziW gene (180 bp) was inserted at EcoRI and 
HindIII sites 
This study 
   
Strains   
S. sahachiroi Azinomycin B producing strain, wild type ATCC 
E. coli DH10B Cloning host Invitrogen 
E. coli 
BL21(DE3) 
Protein expression host Invitrogen 
 
 
 
Cloning, Protein Overexpression, and Purification of AziC2 
aziC2 was cloned in vector pET-24a with BamHI/ HindIII site. The construct 
pET24a-aziC2 was transformed in BL21(DE3) E. coli strain for protein overexpression. 
A 5 mL overnight culture in LB media containing 50 µg/mL kanamycin was added to 1L 
media and grown till an OD600 of 0.8. The culture was induced with 1 mM IPTG and 
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incubated at 16 °C for 22-24 hours prior to harvest. The cells were centrifuged at 
6,000×g for 20 min, washed twice with cold 20 mM Tris-HCl buffer (300 mM NaCl and 
10% glycerol at pH 8) and re-suspended in the same buffer containing 1 mM 
dithiothreitol (DTT) and 1 mM phenyl methylsulfunyl fluoride (PMSF). The cell pellets 
were sonicated on ice water bath using Branson Sonifier 450 (Branson Ultrasonics) 
fitted with a micro tip, output setting 6, duty cycle 50%, for 8 cycles for 30 sec each and 
centrifuged for 1 h at 12,000×g.  
The soluble protein was purified by Nickel affinity chromatography, His Trap TM 
FF 5 ml column (GE Healthcare Life Sciences), according to the instructions provided 
by the supplier (Appendix Figure 3). The purified fractions eluted at 100mM imidazole 
buffer were desalted and concentrated to 2 mg/mL using Amicon® 10K Ultra centrifugal 
filter (EMD Millipore).  
Cloning, Protein Overexpression, and Purification of AziW 
aziW was cloned in vector pET-24b with N-terminal His6-Tag and EcoRI/ 
HindIII site. The construct pET24b-aziW was transformed in BL21(DE3) E. coli strain 
for protein overexpression. A 5 mL overnight culture in LB media containing 50 µg/mL 
kanamycin was added to 1L media and grown till an OD600 of 0.8. The culture was 
induced with 1 mM IPTG and incubated at 16 °C for 24 hours prior to harvest. The cells 
were centrifuged at 6,000×g for 20 min, washed twice with cold 20 mM Tris-HCl buffer 
(300 mM NaCl and 10% glycerol at pH 8) and re-suspended in the same buffer 
containing 1 mM dithiothreitol (DTT) and 1 mM phenyl methylsulfunyl fluoride 
(PMSF). The cell pellets were sonicated on ice water bath using Branson Sonifier 450 
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(Branson Ultrasonics) fitted with a micro tip, output setting 6, duty cycle 50%, for 8 
cycles for 30 sec each and centrifuged for 1 h at 12,000×g. 
The soluble protein was purified by Nickel affinity chromatography, His Trap TM 
FF 5 ml column (GE Healthcare Life Sciences), according to the instructions provided 
by the supplier. The purified fractions eluted at 100mM imidazole buffer were desalted 
and concentrated to 2 mg/mL using Amicon® 10K Ultra centrifugal filter (EMD 
Millipore). To better visualize the protein size on SDS-PAGE, further purification was 
performed on selected fractions. Purified protein fractions were cleaned up by passing 
through Q-sepharose column (Sigma-Aldrich) and eluted with different concentration of 
NaCl buffer (0.10M, 0.25M, 0.50M and 0.75M NaCl). Each fraction was analyzed by 
15% SPS-PAGE. 
In vitro Malachite Green Assay 
A reaction mixture containing 0.75 mg purified AziW, 1 mg purified AziC2, 1 
mM MgSO4, 5 mM L-glutamate or DL-2-aminoadipic acid and 5 mM ATP in 100 mM 
HEPES at pH 8 was incubated at 37C for 30 minutes in a 96-well plate. The reaction 
was terminated by adding an equal volume of 10 mM EDTA (pH 8). The malachite 
green solutions were added to the samples according to the protocol provided in the 
Malachite Green Phosphate Assay Kit (Cayman Chemical). The absorbance of the 
phosphate standards ranging from 1.56 µM to 25 µM (in duplicate) and the samples (in 
triplicate) were measured at 620 nm using BioTek FL800 fluorescence microplate 
reader. 
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Phosphotransferase Activity of AziW using [
32
P]-ATP 
A reaction mixture containing 2 mg of purified AziW, 2 mg of purified AziC2, 5 
mM N-acetyl-L-glutamate, 1 mM MgSO4, 0.1 mCi/mL [γ-
32P]-ATP in 100 mM HEPES 
buffer at pH 8 was incubated at room temperature for 1 hour. The reaction mixture was 
filtered using Amicon® 3K Ultra centrifugal filter. The proteins were loaded into a 15% 
SDS-PAGE gel. After electrophoresis, the gel was washed with buffer containing 5% 
trichloroacetic acid (TCA) and 1% sodium pyrophosphate (NaPPi). The image of the gel 
was visualized using autoradiography. 
L-[
14
C(U)]-glutamate Labeling Assay of AziW 
A reaction mixture containing 2 mg of purified AziW, 2 mg of purified AziC2, 
0.02 mCi/mL L-[14C(U)]-glutamate, 1 mM MgSO4, 5 mM ATP in 100 mM HEPES 
buffer at pH 8 was incubated at room temperature for 3 hours. The reaction mixture was 
filtered using Amicon® 3K Ultra centrifugal filter. The proteins were loaded into a 15% 
SDS-PAGE gel. After electrophoresis, the gel was washed with buffer containing 5% 
trichloroacetic acid (TCA) and 1% sodium pyrophosphate (NaPPi). The image of the gel 
was visualized using autoradiography. 
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CHAPTER III 
 
EXPLORING THE AZABICYCLE BIOSYNTHETIC PATHWAY OF 
AZINOMYCIN B 
INTRODUCTION 
The biosynthetic pathway of the azabicycle of azinomycin B is proposed based 
on literature studies and protein BLAST analysis. Putative substrates and cofactors of the 
corresponding enzymatic reaction are detailed in Figure 17 (Watanabe group). aziC3, 
aziC4, aziC5 and aziC6 genes are involved in the first portion of the proposed 
biosynthetic route to the azabicycle moiety. AziC3 and AziC4 are homology to N-
acetylglutamate kinase and N-acetyl-γ-glutamyl-phosphate reductase of lysine 
biosynthesis while AziC5 and AziC6 are homology to N-terminal transketolase and C-
terminal transketolase of ornithine biosynthesis respectively (Table 2).32 N-acetyl-L-
glutamate is converted into the dihydroxyketone intermediate in four steps. N-
acetylglutamate kinase (AziC3) catalyzes the phosphorylation of the γ-carboxyl group of 
N-acetyl-L-glutamate (a promising substrate for AziC3) using ATP. The phosphorylated 
intermediate converts into a semialdehyde by N-acetyl-γ-glutamyl-phosphate reductase 
(AziC4) and NAD(P)H. The transketolase subunit AziC5 and AziC6 catalyze the 
transfer of two carbons unit from β-hydroxypyruvic acid (HPA) to the semialdehyde 
using thiamine pyrophosphate (TPP) and magnesium (II) ion as cofactors.  
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Figure 17 The proposed biosynthetic route to the azabicycle. 
 
 
 
Previous in vivo gene knockout studies of aziC2 performed by Dinesh Simkhada 
(unpublished data) ceased the production of azinomycin B in Streptomyces sahachiroi, 
which indicated the importance of AziC2 in the azinomycin B formation. Based on this 
result, we continued to explore the function of enzymes subsequent to AziC2 that may 
involve in the azabicycle formation. This chapter details experiments performed in 
verifying the proposed function of each enzyme via both in vitro and in vivo studies. 
 
 
 
 
 
 
 
 
30 
 
Table 2 The proposed function of AziC3, AziC4, AziC5 and AziC6. 
 
Gene Proposed function Organism 
Similarity/ 
Identity (%) 
aziC3 N-acetylglutamate kinase Thermus thermophilus 55/36 
aziC4 
N-acetyl-γ-glutamyl-phosphate 
reductase 
Deinococcus 
geothermalis 
55/45 
aziC5 N-terminal transketolase Thermotoga maritima 61/44 
aziC6 C-terminal transketolase Clostridium perfringens 61/41 
 
 
 
RESULTS AND DISCUSSION 
Protein Overexpression of AziC3, AziC4, AziC5 and AziC6  
 aziC3, aziC4, aziC5 and aziC6 genes were individually cloned in the expression 
vector pET24b and expressed in Escherichia coli BL21(DE3) strain for in vitro assays. 
All proteins were expressed in the soluble form except AziC4, which finally became 
soluble when it was cloned in pET21a (ampicillin resistance) and co-expressed with 
AziC3 (Figure 18). 
 
 
 
 
 
Figure 18 SDS-PAGE gels showing purified AziC3, AziC4, AziC5 and AziC6. 
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Hydroxamate-Fe
3+
 Complex Colorimetric Assay  
Initial experiment to determine the in vitro activity of AziC3 is to identify the 
phosphorylated product. AziC3 catalyzes the conversion of N-acetyl-L-glutamate to N-
acetyl-L-glutamate phosphate intermediate, which is too unstable to be detected using 
mass spectrometry. To overcome the difficulty in trapping unstable intermediate, we 
used hydroxylamine hydrochloride (NH2OHHCl) to convert the phosphate intermediate 
formed into N-acetyl-L-glutamyl-γ-hydroxamate. The N-acetyl-L-glutamyl-γ-
hydroxamate in turn complexes with ferric chloride (FeCl3) at which the absorbance can 
be measured spectrophotometrically (Figure 19).54   
 
 
 
 
 
Figure 19 The formation of hydroxamate-Fe3+ complex by AziC3. 
 
 
 
 
 
Figure 20 Result of hydroxylamine assay by AziC3. 
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One unit of AziC3 is defined as the amount of enzyme catalyzed the formation of 
1µmole of N-acetyl-L-glutamyl-γ-hydroxamate-Fe3+ complex per minute under the 
assay conditions. The molar absorption coefficient ε of this complex at 540nm is 0.5188 
M-1cm-1. Based on this information, the concentration of N-acetyl-L-glutamyl-γ-
hydroxamate-Fe3+ complex in µM was calculated (A = εlc) and plotted against the 
reaction time at 37C (Figure 20). This result primarily confirmed the activity of AziC3. 
[γ-32P]-ATP Labeling Assay  
To further characterize the phosphorylated intermediate, [γ-32P]-ATP was used to 
label the carboxylic group of N-acetyl-L-glutamate during the AziC3 enzymatic reaction. 
A reaction containing AziC3, N-acetyl-L-glutamate, and [γ-32P]-ATP was set up. After 
the reaction, the protein was removed and the reaction mixture was spotted on a reverse 
phase TLC plate. The TLC plate was developed using chloroform/butanol mixture and 
visualized using autoradiography. Unreacted [γ-32P]-ATP is polar and did not move on 
the TLC plate. The [γ-32P] labeled product N-acetyl-L-glutamate phosphate is 
comparably less polar and traveled up the TLC plate as shown in Figure 21. This 
experiment identified the phosphorylated intermediate which is in consistent with the 
initial experiment. 
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Figure 21 Image of reverse phase TLC plate of AziC3 [γ-32P]-ATP labeling study. 
 
 
 
Synthesis of Substrate Analog: N-acetyl-glutamate Cysteamine 
 
 
Scheme 1 Proposed synthetic route to N-acetyl-glutamate cysteamine. 
 
 
 
To better mimic the putative biosynthetic intermediate for AziC3 enzymatic 
reaction, we attempted to synthesize the peptidyl carrier protein (PCP)-linked N-acetyl-
L-glutamate. The synthetic strategy is outlined in Scheme 1. Acetylation of glutamate-γ-
benzyl ester 1 generated the acetylated product 2 (Appendix Figure 5).55 Hydrolysis of 
the unprotected carboxylic group with N-acetyl-cysteamine yielded the cysteamine-
linked acetyl-glutamate-γ-benzyl ester 3 (Appendix Figure 6).56 Deprotection of benzyl 
ester group to give the desired final product 4.55 Unfortunately, we are unable to remove 
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the benzyl ester group in the final step due to poisoning of catalyst used for 
hydrogenation. Palladium and platinum was used as the catalyst with increased reaction 
pressure, however no conversion occurred. 
Gene Knockout and Complementation Study of AziC3 
 
 
Figure 22 An outline of the in vivo analysis of AziC3. 
 
 
 
In vitro characterization of proteins function may not completely prove their 
involvement in the azinomycin B biosynthesis. To better understand their role in the 
original strain (Streptomyces sahachiroi), gene knockout study is usually performed in 
parallel. aziC3 gene disruption was carried out. Thiostrepton (tsr) resistance gene and 
the upstream and downstream regions of aziC3 were cloned into the E. coli-
Streptomyces shuttle vector pKC1139 (aparamycin resistance). Intergeneric conjugation 
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was performed between the plasmid in E. coli S-17 strain and Streptomyces sahachiroi 
wild-type spore. The wild-type Streptomyces sahachiroi will become resistant to both 
aparamycin and thiostrepton upon successful conjugation. After several generations, 
gene crossover should occur and the mutant strain would become thiostrepton resistance 
and sensitive to aparamycin. In our case, the conjugal transformation was successful; 
however no cross-over had occurred after 30th generations. We are unable to explain the 
circumstance and have been working on the conjugation steps. Figure 22 detailed the 
entire process of gene disruption and complementation. The azinomycin B production of 
the restored and mutant strain will finally be analyzed by using HPLC. 
Kinetic Measurement of AziC3 and AziC4 Coupling Reaction 
Characterization of AziC4 is assayed in conjunction with AziC3 due to the 
instability of phosphate intermediate as its substrate. The activity of AziC4 was 
determined by a coupled reaction with AziC3. AziC4 catalyzes the formation of N-
acetyl-L-glutamate semialdehyde from a very unstable substrate N-acetyl-L-glutamate 
phosphate using NAD(P)H. In the coupling reaction, N-acetyl-L-glutamate was first 
converted into N-acetyl-L-glutamate phosphate by AziC3 and then further reduced to N-
acetyl-L-glutamate semialdehyde by AziC4 while NAD(P)H was oxidized to NAD(P)+. 
The rate of NAD(P)H oxidation was monitored as a change in absorbance at 340nm 
using UV-vis spectrophotometer (Figure 23).57 The rate of NAD(P)+ formation is equal 
to the rate of product formation. The kinetic data is reported in Table 3. 
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Figure 23 Result of AziC3 and AziC4 coupling assay. NADH (left) and NADPH (right). 
 
 
 
Table 3 Kinetic data of AziC3 and AziC4 coupling assay. 
 
Kinetic data 
N-acetyl-Glu/ ATP/ 
NADH 
N-acetyl-Glu/ ATP/ 
NADPH 
[AziC4] 4.13 uM 4.13 uM 
Vmax  0.02105 mM/min 0.03084 mM/min 
Km  0.6859 mM-1 1.2220 mM-1 
Kcat/ Km 5.098 mM-1min-1 7.468 mM-1min-1 
 
 
 
 AziC4 accepts both NADH and NADPH as a cofactor and did not show a 
significant preference to either one of them. Optimizing the reaction conditions may 
reveal the actual cofactor of this reaction and give us a more accurate kinetic result. 
Nonetheless, these data give us enough confident to move on to characterize AziC5 and 
AziC6 using the putative substrates.  
SIGNIFICANCE 
Though these protein function is quite common in the biosynthesis of natural 
compounds, characterizing them are valuable for us to fully understand the biosynthesis 
of the azabicycle moiety. If the role of AziW in the azabicycle biosynthetic pathway is 
 
 
37 
 
confirmed, we will be able to repeat the in vitro assays performed with AziC3 and/or 
AziC4 by using AziW in place of acetyl-CoA. The substrate preference and the rate of 
reaction can be compared. Further experiments for AziC5, AziC6, and the enzymes 
involved in the rest of the azabicycle biosynthetic pathway will depend upon the success 
in synthesizing substrate analogs. 
EXPERIMENTAL PROCEDURES 
Instrumentation and General Methods 
All primers used for DNA amplifications were ordered through Gene 
Technologies Lab (GTL) at Texas A&M University. DNA sequencing was also 
performed by GTL. All chemicals were purchased from Sigma-Aldrich. Kinetic data 
were measured using spectronic gensys spectrophotometer. Protein concentrations were 
analyzed via Bradford method (Standard: Bovine serum albumin with linear range of 0.5 
mg/mL to 5 mg/mL). Radioactive labeled compounds were obtained from Perkin Elmer. 
Autoradiograph is developed using Fuji X-ray film developer. Primers, plasmids and 
strains used in this study are listed in Table 4. The map of the plasmid constructs is 
presented in Appendix Figure 7.  
 
 
 
Table 4 Primers, plasmids and strains used in the AziC3, AziC4, AziC5 and AziC6 
studies. 
 
Primer/ plasmid/ 
strain 
Description Source 
Primers   
aziC3_ EcoRI_F GCGAATTCATGGCGCAGGATCCGAGG This study 
aziC3_ HindIII_R CCAAGCTTGCCATCTTCGGGCCTCTCC This study 
aziC3_UP_F GCAAGCTTACACATGACTACGGCGCTG This study 
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Table 4 Continued 
Primer/ plasmid/ 
strain 
Description Source 
aziC3_UP_R GCAGATCTCGCCACGTTCAGGCTCT This study 
aziC3_DN_F GCTCTAGACGACCGGATGGCCGAG This study 
aziC3_DN_R GCCTTAAGAGCGGTCGAGGAGGATCAG This study 
aziC4_BamHI_F AGGATCCATGCATGCCCACCCCAAGCT This study 
aziC4_HindIII_R GAAGCTTGGCGGGGTGCAGTCCGGT This study 
aziC5_EcoRI _F AGAATTCATGAGCCGCCCGCCGCTC This study 
aziC5_HindIII_R AAGCTTCGCCGTACCTCCCTGCACGG This study 
aziC6_EcoRI _F GAATTCATGACGACGGCGCGCCCC This study 
aziC6_HindIII_R AAAGCTTTCCCCTCATGGTTGGGCCGG This study 
   
Plasmids   
pGEM-T easy Sub-cloning vector, E. coli Promega 
pET-21a T7 expression vector, C-terminal His6-Tag, 
Ampicillin resistance 
Novagen 
pET-24b T7 expression vector, C-terminal His6-Tag, 
Kanamycin resistance 
Novagen 
pET24b-aziC3 aziC3 gene (879 bp) was inserted at EcoRI and 
HindIII sites 
This study 
pET21a-aziC4 aziC4 gene (924 bp) was inserted at BamHI and 
HindIII sites 
This study 
 
pET24b-aziC5 aziC5 gene (936 bp) was inserted at EcoRI and 
HindIII sites 
This study 
 
pET24b-aziC6 aziC6 gene (1023 bp) was inserted at EcoRI and 
HindIII sites 
This study 
 
pkC1139 E. coli-Streptomyces shuttle vector, Aparamycin 
resistance 
 
pkC1139-
aziC3_UP 
Upstream region (1113 bp) of aziC3 was inserted at 
HindIII and XbaI sites 
This study 
pkC1139-
aziC3_DN 
Downstream region (1105 bp) of aziC3 was inserted 
at XbaI and EcoRI sites 
This study 
   
Strains   
S. sahachiroi Azinomycin B producing strain, wild type ATCC 
S. lividans TK24 Heterologous expression strain, wild type ATCC 
E. coli DH10B Cloning host Invitrogen 
E. coli 
BL21(DE3) 
Protein expression host Invitrogen 
E. coli S-17 Intergeneric conjugation, donor strain Invitrogen 
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Cloning, Protein Overexpression, and Purification of AziC3, AziC4, AziC5 and 
AziC6 
aziC3, aziC5, and aziC6 were individually cloned in vector pET-24b. aziC4 was 
cloned in vector pET-21a. The construct was transformed in BL21(DE3) E. coli strain 
for protein overexpression. A 5 mL overnight culture in LB media containing 50 µg/mL 
kanamycin (100 µg/mL ampicillin for pET21a-aziC4) was added to 1L media and grown 
till an OD600 of 0.8. The culture was induced with 1 mM IPTG and incubated at 16 °C 
for 22-24 hours prior to harvest. The cells were centrifuged at 6,000×g for 20 min, 
washed twice with cold 50 mM phosphate buffer (300 mM NaCl and 10% glycerol at pH 
7) and re-suspended in the same buffer containing 1 mM dithiothreitol (DTT) and 1 mM 
phenyl methylsulfunyl fluoride (PMSF). The cell pellets were sonicated on ice water 
bath using Branson Sonifier 450 (Branson Ultrasonics) fitted with a micro tip, output 
setting 6, duty cycle 50%, for 8 cycles for 30 sec each and centrifuged for 1 h at 
12,000×g.  
The soluble protein was purified by Nickel affinity chromatography, His Trap TM 
FF 5 ml column (GE Healthcare Life Sciences), according to the instructions provided 
by the supplier. The purified fractions were desalted and concentrated using Amicon® 
10K Ultra centrifugal filter (EMD Millipore).  
Heterologous Expression of AziC3 
A construct consisted of the upstream region (1113 bp) and downstream region 
(1105 bp) of aziC3 and a thiostrepton (tsr) resistance gene was created in the E. coli-
Streptomyces shuttle vector pKC1139 (aparamycin resistance) . The thiostrepton gene 
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was inserted in between the regions. The construct in E. coli S-17 donor strain was 
transformed into S. sahachiroi wild-type spore via intergeneric conjugation.  
A 5 mL culture of E. coli S-17 containing the pKC1139-aziC3 was grown to an 
OD600 of 0.4 with 50 mg/mL aparamycin. The cells were pelleted,  washed with LB and 
re-suspended in 200 µL of LB. S. sahachiroi wild-type spore was grown on MS agar 
plate ( 20 g/L soy flour, 20 g/L manitol, 20 g/L LB agar and 2.03 g/L MgCl2H2O)  at 
30C for 7-10 days. The spores were suspended in 6 mL 2XYT medium (16 g/L difco 
bacto trypton, 10 g/L difco bacto yeast extract, 5 g/L NaCl and 40 µL 5N NaOH), 
filtered and heat shocked at 70C for 10 minutes to activate germination. The spores 
were incubated at 37C for 3-5 hours with shaking. After incubation, it was washed with 
2XYT and re-suspended in 500 µL of 2XYT. Equal volume of E. coli and S. sahachiroi 
cultures were mixed thoroughly and plated on MS agar plates. The plates were incubated 
at 30C for 16-22 hours prior to overlay with 50 µg/mL aparamycin and 25 µg/mL 
nalidixic acid.  
[
32
P]-ATP labeling study of AziC3 
A reaction mixture contained 0.5 mg/mL purified AziC3, 10mM N-acetyl-L-
glutamate, 20mM MgCl2, 0.2mCi/mL [γ-
32P]-ATP and 100mM potassium phosphate 
buffer at pH 7.5 was incubated at room temperature for 16 hours. The reaction mixture 
was filtered using Amicon® 10K Ultra centrifugal filter to remove the protein and the 
flow through was spotted on reverse phase TLC plate. The TLC plate was developed 
using chloroform/butanol mixture (1:4-V/V% or 2:3-V/V%) and visualized using 
autoradiography.  
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Colorimetric Assay of AziC3 
A mixture consisted of 400 mM NH2OHHCl, 400 mM Tris-HCl, 20 mM MgCl2 
and 10 mM ATP was first adjusted to pH 7.2 using NaOH. The mixture was transferred 
into a microcuvette. 0.5 mg/mL purified AziC3 was added. The reaction was started by 
adding 40 mM N-acetylglutamate (pH 7). After incubated at 37C for a certain period of 
time (15 minutes to 1 hour/ overnight), the reaction was terminated by adding an equal 
volume of a solution containing 5% (w/v) FeCl36H2O, 8% (w/v) trichloroacetic acid, 
and 0.3 M HCl. The absorbance was measured at 540 nm spectronic gensys 
spectrophotometer. 
Synthesizing N-acetyl-glutamate Cysteamine 
1 equivalent (0.2 g) of glutamate-γ-benzyl ester, 1.5 equivalents (100 µL) of 
acetyl chloride and 2 equivalents (0.14 g) of NaHCO3 in 5 mL DCM were stirred at 
room temperature for 24 hours. The reaction mixture was filtered and rotavapored to 
remove NaHCO3 and DCM. The acetylated product was purified using column 
chromatography (2% methanol in chloroform).  
1 equivalent (2 g) of the acetylated product, 1 equivalent (0.85 g) of N-
acetylcysteamine and 1 equivalent (0.88 g) of dimethylaminopyridine (DMAP) in 25 mL 
DCM were stirred on ice/acetone bath for 15 minutes.  1 equivalent (1 g) of N, N′-
dicyclohexylcarbodiimide (DCC) was added dropwise to the reaction mixture and it was 
stirred at room temperature for 20 hours. The reaction mixture was filtered through 
celite, washed with DCM, extracted with saturated NaHCO3 and NaCl and dried using 
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MgSO4. The cysteamine-linked product was purified using column chromatography (2% 
methanol in chloroform).  
Continuous reaction of AziC3 and AziC4  
A reaction mixture consisted of N-acetylglutamate (0.05 mM to 1 mM at pH 7), 
10 mM ATP, 0.3 mM NAD(P)H, 20 mM MgCl2 and 100 mM phosphate buffer (pH 7.2) 
was kept at 4C in a microcuvette. 2 mg/mL of purified AziC3 and AziC4 protein 
mixture (co-expressed) was added to the mixture. The rate of decrease in the 
concentration of NAD(P)H was measured immediately at 340 nm using UV-vis 
spectrophotometer over a period of 180 seconds.  
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CHAPTER IV 
 
MECHANISTIC STUDY OF THE ENZYMES INVOLVED IN SULFATION  
INTRODUCTION  
Anti-tumor agents usually covalently bind to their targets through specific 
moieties in their structures. Common DNA alkylating groups of natural product are 
cyclopropane, epoxide, and aziridine rings. These highly strained three-membered ring 
systems cross-link with double-stranded DNA. Mitomycin C and dynemicin A are 
examples of three-membered ring containing drugs used in cancer treatment. The mode 
of action of mitomycin C (Figure 24) and dynemicin A (Figure 25) are depicted below. 
Mitomycin C is first activated by a two electrons quinone reduction to form a 
hydroquinone. The hydroquinone intermediate losses a methanol group, follows by a 
proton-assisted aziridine ring opening, and then alkylates DNA.58 DNA cleavage by 
dynemicin A is induced by NAPDH. The activated dynemicin A cut the 3’ side of purine 
bases at specific positions such as 5’-GT, 5’-GC and 5’-AG to cause DNA damage.59 
The biosynthesis of these compounds have been of research interest for many years. The 
understanding of how these unique ring structures are formed will provide valuable 
information in future drug development.  
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Figure 24 The mode of action of mitomycin C: DNA cross-link. Adapted from Cummings et al. [58]. 
 
 
 
 
 
Figure 25 The mode of action of dynemicin A: DNA cleavage. Adapted from Sugiura et al. [59]. 
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Azinomycin B is one of the potent anti-tumor agents consists of the aziridine 
group under study. The mechanism of its aziridine ring formation is by far the most 
interesting part of the azabicycle moiety because very little is known about its 
biosynthesis. Out of all the aziridine-containing natural products identified, only three of 
them have their gene cluster published, which includes azinomycin, azicemicin, and 
mitomycin. A possible mechanism for the aziridine ring formation proposed by Bicker 
and Fischer is as follow: sulfotransferases convert the -amino alcohol to sulfate ester 
intermediate using PAPS, which is formed by ATP and SO4
2- enzymatically, and 
subsequent ring closure gives the aziridine (Figure 10).50 Based on this observation and 
sequence homology analysis (Table 5), we proposed a mechanistic scheme of the 
aziridine ring formation (Figure 26). 
 
 
 
 
 
Figure 26 The proposed mechanistic scheme of the aziridine ring formation. 
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Table 5 The proposed function of AziH1, AziH2, and AziH3. 
 
Gene Proposed function Organism 
Similarity/ 
Identity (%) 
aziH1 Sulfate adenyltransferase subunit II Escherichia coli 46/63 
 
or PAPS reductase/ PAPS 
sulfotransferase 
 
 
aziH2 Sulfate adenyltransferase subunit I Escherichia coli 47/63 
aziH3 Adenylsulfate kinase/ APS kinase Escherichia coli 41/59 
 
 
 
The in vivo gene knockout study of aziH1 and aziH2 (performed by Huitu 
Zhang) showed a decrease in azinomycin B production. The in vitro studies of the 
aziridine ring formation are currently in progress. 
RESULTS AND DISCUSSION 
Protein Overexpression of AziH1, AziH2 and AziH3  
aziH1, aziH2 and aziH3 were individually cloned in the expression vector 
pET24b (kanamycin resistance) and expressed in Escherichia coli BL21 (DE3) strain. 
AziH3 was expressed as a soluble protein and purified using His-Trap column. AziH1 
and AziH2 are not quite soluble and we are experiencing difficulties in the purification 
processes. Different cloning strategies and expression conditions were attempted; 
however, there were no improvement in protein solubility (Figure 27). The protein size 
of AziH3 shows up bigger on the SDS-PAGE gel but the actual size of AziH3 has been 
confirmed by MALDI-MS (Appendix Figure 8). 
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Figure 27 SDS-PAGE of insoluble proteins AziH1 and AziH2 and purified AziH3. 
 
 
 
SIGNIFICANCE 
One of the most challenging parts in enzymatic study is to obtain soluble, active 
and purified proteins. Protein solubility is a common problem when it is expressed in a 
foreign host. Strategies like modifying expression conditions, co-expressing with soluble 
protein or as a fusion protein and optimizing DNA codon usage to meet the host 
preference may solve the solubility problem. However, optimizing expression conditions 
and protein co-expression have failed with AziH1 and AziH2. Other practical 
approaches include expressing the proteins in Streptomyces lividans, synthesizing the 
genes with codon usage optimized for E. coli., purifying the proteins from inclusion 
body, or expressing them as a fusion protein. The last resort will be to perform the 
enzymatic studies using crude AziH1 and AziH2.  
EXPERIMENTAL PROCEDURES 
Instrumentation and General Methods 
All primers used for DNA amplifications and DNA sequencing services were 
provided by Gene Technologies Lab (GTL) at Texas A&M University. Protein 
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concentrations were analyzed via Bradford method (Standard: Bovine serum albumin 
with linear range of 0.5 mg/mL to 5 mg/mL). Primers, plasmids and strains used in this 
study are listed in Table 6. The map of the plasmid constructs is presented in Appendix 
Figure 9.  
 
 
 
Table 6 Primers, plasmids and strains used in the AziH1, AziH2 and AziH3 studies. 
 
Primer/ plasmid/ 
strain 
Description Source 
Primers   
aziH1_ EcoRI_F CCGAATTCAAGCCGATGATCCTGTTCTC This study 
aziH1_ HindIII_R CAAGCTTGAAGTACCCCTCACGCTTGC This study 
aziH2_ EcoRI_F GGCGAATTCATGAGTGGATCCACCGGACGGT
GG 
This study 
aziH2_ HindIII_R CAAGCTTGCCGGTGACGGCCGCGCC This study 
aziH3_EcoRI_F GGGAATTCATGATCGGGCCTGAATCATGTG This study 
aziH3_HindIII_R GGAAGCTTTGCCACGAACCGCTTCCG This study 
   
Plasmids   
pGEM-T easy Sub-cloning vector, E. coli Promega 
pET-24b T7 expression vector, C-terminal His6-Tag, 
Kanamycin resistance 
Novagen 
pET24b-aziH1 aziH1 gene (813 bp) was inserted at EcoRI and 
HindIII sites 
This study 
pET21a-aziH2 aziH2 gene (1308 bp) was inserted at EcoRI and 
HindIII sites 
This study 
 
pET24b-aziH3 aziH3 gene (558 bp) was inserted at EcoRI and 
HindIII sites 
This study 
 
   
Strains   
E. coli DH10B Cloning host Invitrogen 
E. coli 
BL21(DE3) 
Protein expression host Invitrogen 
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Cloning, Protein Overexpression, and Purification of AziH1, AziH2 and AziH3  
aziH1, aziH2, and aziH3 were individually cloned in vector pET-24b. The 
construct was transformed in BL21(DE3) E. coli strain for protein overexpression. A 5 
mL overnight culture in LB media containing 50 µg/mL kanamycin was added to 1L 
media and grown till an OD600 of 0.8. The culture was induced with 1 mM IPTG and 
incubated at 16 °C for 22-24 hours prior to harvest. The cells were centrifuged at 
6,000×g for 20 min, washed twice with cold 50 mM phosphate buffer (300 mM NaCl 
and 10% glycerol at pH 7) and re-suspended in the same buffer containing 1 mM 
dithiothreitol (DTT) and 1 mM phenyl methylsulfunyl fluoride (PMSF). The cell pellets 
were sonicated on ice water bath using Branson Sonifier 450 (Branson Ultrasonics) 
fitted with a micro tip, output setting 6, duty cycle 50%, for 8 cycles for 30 sec each and 
centrifuged for 1 h at 12,000×g.  
The soluble protein was purified by Nickel affinity chromatography, His Trap TM 
FF 5 ml column (GE Healthcare Life Sciences), according to the instructions provided 
by the supplier. The purified fractions were desalted and concentrated using Amicon® 
10K Ultra centrifugal filter (EMD Millipore).  
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CHAPTER V 
 
CONCLUSION 
Advancement in bioinformatics and high-throughput compound screening 
accelerated the process of identifying new and valuable natural compounds. The studies 
on newly isolated natural products’ biosynthesis also reveal interesting chemical 
pathways and novel reactions. Since drug design predominately relies on structural 
modification and optimization of existing compounds, refine understanding of the 
structural origins of various classes of natural products and their related biosynthesis will 
undoubtedly improve natural product-based drug development in the future.  
Azinomycin B, a secondary metabolite isolated from Streptomyces sahachiroi, 
exhibits excellent antitumor activity and mode of action through its rare and complex 
structural makeup. The compound’s aziridine and epoxide moieties are responsible for 
its promising bioactivity via dsDNA interstrand crosslinks in selected tumor types. 
Understanding the biosynthetic process of these unique structural aspects of azinomycin 
B offers important insights towards its in vivo activities as well as target specificity. 
Therefore, we aim to characterize the important biosynthetic pathways of azinomycin B 
at the mechanistic level. Although it is extremely challenging to completely map out 
azinomycin B’s biosynthetic routes experimentally, the use of bioinformatics had helped 
us narrow down the putative components required in each step of the biosynthesis. 
AziW catches our attention when the in vitro and in vivo studies of AziC2 were 
inconclusive and suggested a possible existence of a partner protein. Through a series of 
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in vitro isotope-feeding experiments, AziW was proven to play a role in the assembly of 
azinomycin B’s azabicycle moiety during the natural product’s biosynthesis. The next 
step in this project includes the use of mass spectrometry to corroborate our 
experimental observation and strengthen our hypothesis.  
Our research interest in the azabicycle moiety includes the genes downstream of 
aziC2. This particular biosynthetic route contains many unknown steps such as the 
aziridine ring closure that we believe are chemically novel. In order to fully characterize 
the downstream biosynthetic reactions, we have to investigate the pathway sequentially. 
Since we have successfully proved the function of AziC3 (N-acetylglutamate kinase) 
and AziC4 (N-acetyl-γ-glutamyl-phosphate reductase), which frequently work together 
to convert the γ-carboxylic acid group of N-acetylglutamate to an aldehyde, we expect to 
find a downstream N-acetyl-dihydroxyketone to complete the biosynthesis of the 
azabicycle. Essentially, the complete characterization of the azabicycle biosynthesis can 
broaden the understanding of azinomyicin B’s mode of action.  
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APPENDIX 
 
 
Appendix Figure 1 Amino acid sequence alignment of AziC2 with LysX homologs.                                                 
Amino acid important for LysX and LysW interaction based on electrostatic surface mapping (red arrow). 
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Appendix Figure 2 Gene clusters of lysine biosynthetic enzymes from different species. Pink: LysW 
homologs; Red: LysX homologs; Orange: LysY homologs; Yellow: LysZ homologs; Blue: LysJ 
homologs; Navy: LysK homologs. Adapted from Horie et al. [53]. 
 
Appendix Figure 3 SDS-PAGE of purified AziW.                                     
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Appendix Figure 4 aziW-pET24b and aziC2-pET24a constructs. 
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Appendix Figure 5 
1H-NMR of acetylated glutamate-γ-benzyl ester. 
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Appendix Figure 6 
1H-NMR and mass spectrum of cysteamine-linked acetyl-glutamate-γ-benzyl ester. 
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Appendix Figure 7 aziC3-pET24b, aziC4-pET21a, aziC5-pET24b and aziC6-pET24b constructs. 
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Appendix Figure 8 MALDI-MS of AziH3. 
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Appendix Figure 9 aziH1-pET24b, aziH2-pET21a and aziH3-pET24b constructs. 
